Mitragynine and Morphine Bind Same Receptor But Stabilize Different Conformations, Explaining Distinct Pharmacology

Why it matters

This structural study explains at a molecular level why mitragynine produces different effects than morphine despite binding the same receptor—information critical for designing safer pain medications and understanding kratom's unique pharmacology.

The big picture

Both mitragynine and morphine activate the mu-opioid receptor (μOR), but kratom's primary alkaloid is known for causing fewer respiratory and addiction side effects than classical opioids. Understanding why requires looking at exactly how each compound docks into the receptor at the atomic level. University of Houston researchers used 1-microsecond molecular dynamics simulations to map these differences with unprecedented detail.

Key findings

• Mitragynine and morphine bind the same orthosteric pocket in the μ-opioid receptor but adopt distinct conformations during 1-microsecond simulations
• (-)-Mitragynine showed the lowest average binding free energy and maintained the shortest distance (4 Å) to key residue Asp-147, indicating stronger, more stable binding
• 7-OH showed higher receptor affinity than morphine in docking scores (-7.8 kcal/mol vs -6.78 kcal/mol for morphine)
• Morphine adopts a broader, more scattered energy landscape suggesting greater conformational flexibility—potentially underlying its broader side-effect profile
• The differential receptor conformations stabilized by mitragynine vs. morphine may explain why mitragynine preferentially activates G-protein pathways over β-arrestin, linked to fewer side effects

What they say

The authors conclude: "Mitragynine and its derivatives stabilized distinct conformational populations compared with morphine, which may contribute to their differing biases toward downstream signaling pathways."

Bottom line

A molecular dynamics study from University of Houston shows mitragynine locks the opioid receptor into a different shape than morphine, providing a structural explanation for kratom's biased opioid signaling and potential therapeutic advantages.